Market closed
Tango Therapeutics/$TNGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tango Therapeutics
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Ticker
$TNGX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
155
Website
TNGX Metrics
BasicAdvanced
$139M
-
-$1.19
0.80
-
Price and volume
Market cap
$139M
Beta
0.8
52-week high
$12.02
52-week low
$1.11
Average daily volume
737K
Financial strength
Current ratio
6.978
Quick ratio
6.757
Long term debt to equity
17.061
Total debt to equity
18.291
Management effectiveness
Return on assets (TTM)
-25.31%
Return on equity (TTM)
-57.58%
Valuation
Price to revenue (TTM)
3.349
Price to book
0.7
Price to tangible book (TTM)
0.7
Price to free cash flow (TTM)
-1.065
Growth
Revenue change (TTM)
15.17%
Earnings per share change (TTM)
10.89%
3-year revenue growth (CAGR)
4.33%
3-year earnings per share growth (CAGR)
8.36%
What the Analysts think about TNGX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Tango Therapeutics stock.
TNGX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
TNGX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
TNGX News
AllArticlesVideos
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
GlobeNewsWire·4 weeks ago
Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights
GlobeNewsWire·2 months ago
Tango Therapeutics: Chance For A Short Squeeze
Seeking Alpha·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Tango Therapeutics stock?
Tango Therapeutics (TNGX) has a market cap of $139M as of April 19, 2025.
What is the P/E ratio for Tango Therapeutics stock?
The price to earnings (P/E) ratio for Tango Therapeutics (TNGX) stock is 0 as of April 19, 2025.
Does Tango Therapeutics stock pay dividends?
No, Tango Therapeutics (TNGX) stock does not pay dividends to its shareholders as of April 19, 2025.
When is the next Tango Therapeutics dividend payment date?
Tango Therapeutics (TNGX) stock does not pay dividends to its shareholders.
What is the beta indicator for Tango Therapeutics?
Tango Therapeutics (TNGX) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.